About CalciMedica
CalciMedica is a company based in San Diego (United States) founded in 2006 by Kenneth Stauderman.. CalciMedica has raised $76.66 million across 16 funding rounds from investors including Biogen, HHS and Avenue Capital Group. The company has 14 employees as of December 31, 2024. CalciMedica offers products and services including Auxora and CRAC Channel Inhibitors. CalciMedica operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter San Diego, United States
- Employees 14 as on 31 Dec, 2024
- Founders Kenneth Stauderman
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Calcimedica, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-13.7 M60.12as on Dec 31, 2024
-
EBITDA
$-24.15 M-10.68as on Dec 31, 2024
-
Total Equity Funding
$76.66 M (USD)
in 16 rounds
-
Latest Funding Round
$32.5 M (USD), Debt – Conventional
Apr 06, 2025
-
Investors
Biogen
& 7 more
-
Employee Count
14
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CalciMedica
CalciMedica is a publicly listed company on the NASDAQ with ticker symbol CALC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CalciMedica
CalciMedica offers a comprehensive portfolio of products and services, including Auxora and CRAC Channel Inhibitors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
CRAC channel inhibitor targeting inflammatory diseases in pancreas and kidney
Modulates immune responses for lung and organ inflammation treatments
Unlock access to complete
Unlock access to complete
Funding Insights of CalciMedica
CalciMedica has successfully raised a total of $76.66M across 16 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $32.5 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 16
- Last Round Debt – Conventional — $32.5M
-
First Round
First Round
(31 Jul 2007)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2025 | Amount | Debt – Conventional - CalciMedica | Valuation |
investors |
|
| Apr, 2023 | Amount | Post-IPO - CalciMedica | Valuation |
investors |
|
| May, 2020 | Amount | Series C - CalciMedica | Valuation | Valence Life Sciences |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CalciMedica
CalciMedica has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, HHS and Avenue Capital Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investments in distressed debt and securities are managed globally.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CalciMedica
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CalciMedica
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Calcimedica Comparisons
Competitors of CalciMedica
CalciMedica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Calcimedica
Frequently Asked Questions about CalciMedica
When was CalciMedica founded?
CalciMedica was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Where is CalciMedica located?
CalciMedica is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is CalciMedica a funded company?
CalciMedica is a funded company, having raised a total of $76.66M across 16 funding rounds to date. The company's 1st funding round was a Series C of $17.19M, raised on Jul 31, 2007.
How many employees does CalciMedica have?
As of Dec 31, 2024, the latest employee count at CalciMedica is 14.
What does CalciMedica do?
CalciMedica was established in 2006 in San Diego, United States, within the biotechnology sector. A portfolio of selective CRAC channel inhibitor drugs is being advanced by the company to address acute inflammatory conditions. Development efforts are directed toward enhancing patient outcomes in these indications, with operations centered on pharmaceutical innovation for inflammatory diseases.
Who are the top competitors of CalciMedica?
CalciMedica's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
What products or services does CalciMedica offer?
CalciMedica offers Auxora and CRAC Channel Inhibitors.
Is CalciMedica publicly traded?
Yes, CalciMedica is publicly traded on NASDAQ under the ticker symbol CALC.
Who are CalciMedica's investors?
CalciMedica has 8 investors. Key investors include Biogen, HHS, Avenue Capital Group, Valence Life Sciences, and Mesa Verde Venture Partners.
What is CalciMedica's ticker symbol?
The ticker symbol of CalciMedica is CALC on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.